By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience announced after the close of the market on Thursday that it has reached an agreement with Premier healthcare alliance to offer members of the alliance Meridian's illumigene C. difficile and illumigene Group B Streptococcus molecular tests.

Meridian will offer the two tests to the 2,500 US hospitals and more than 81,000 other healthcare sites that are part of Premier at specially negotiated prices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.